Company insight
Too much screen time can lead to a strain on our eyes, especially in children who use digital devices a lot.
eye strain. Over 84 days, participants were assessed across multiple visits, undergoing clinical and visual tests before and after one hour of controlled digital activity (a self-selected video game). The results showed that daily astaxanthin supplementation significantly reduced both subjective and objective measures of eye strain: ■ Chronic digital eye strain decreased by 20% (p<0.05).
■ Acute digital eye strain decreased by 27% (p=0.01).
■ Improvements were observed in stereopsis (depth perception), pupillary light reflex and tear production.
Overall, findings suggest that astaxanthin enhances visual endurance, reduces oxidative stress and improves ocular hydration, making it a promising solution for children experiencing screen-related eye strain. Importantly, no adverse effects were reported, highlighting its safety for long-term use at the recommended daily dose.
Child-friendly formulations and regulatory approval
Astaxanthin-rich oleoresin is an approved novel food in Europe and can be
22
incorporated into child-friendly formats such as gummies, chewabless and confectionery. The maximum authorised daily doses for children in Europe are: ■ 3 to <10 years: 2.3mg/day ■ 10 to <14 years: 5.7mg/day ■ 14+ years: 8mg/day
This allows for the development of palatable, easy-to-consume products that can support children’s visual health in a convenient way.
Industry implications: addressing the digital screen challenge The widespread use of digital screens among children has raised concerns about visual health, cognitive development, sleep quality and mental well-being. While some authorities advocate for limiting screen time, others emphasise the responsible development of digital technologies. Meanwhile, there is a major opportunity for the nutraceutical industry to provide scientifically validated solutions. AstaReal astaxanthin supplementation offers a safe, natural and evidence-based approach to reducing digital eye strain and supporting paediatric and adult’s vision health. By incorporating astaxanthin into functional
foods and dietary supplements (subject to local market regulations), the industry can meet the growing demand for preventive eye health solutions tailored to modern digital lifestyles. AstaReal, with over 75 human clinical studies, is dedicated to contributing to a sustainable and healthy future for all.
AstaReal is a global leader in natural astaxanthin production, R&D and clinical science, with clinically proven solutions to enhance health and well-being. With origins in Uppsala University, Sweden, AstaReal was first to commercially produce natural astaxanthin and introduced the Astaxin supplement in 1995. The company supplies natural astaxanthin to supplement manufacturers and produces its own branded products. By continuing to invest in research and development, the company’s aim is to further explore new applications that can improve health and well-being worldwide. AstaReal is part of the AstaReal Group, fully owned by Fuji Chemical Industries, with its European headquarters in Stockholm. ●
References available upon request.
www.astareal.se. Ingredients Insight /
www.ingredients-insight.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94
